Physician
American Medical Group INC.
American Medical Group INC. was paid $25.58M by Medicaid between Jan 2018 and Dec 2024, across 126 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 35% of everything it billed.
33Billing provider infoAMERICAN MEDICAL GROUP INC.
HOBBS, NM 88240
HOBBS, NM 88240
33aNPI1255441051assigned 08/30/2006
33bProvider typeOccupational Medicine Physician
28Total paid$25.58M
24GClaims467,695
24DCodes billed126
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 69,903 | $3.33M | |
| 2019 | 68,414 | $3.49M | |
| 2020 | 54,094 | $2.69M | |
| 2021 | 63,554 | $3.03M | |
| 2022 | 78,585 | $3.98M | |
| 2023 | 71,403 | $4.30M | |
| 2024incomplete | 61,742 | $4.76M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 35% | 93,769 | 86,028 | $8.98M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 34% | 126,905 | 118,044 | $8.82M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 5.4% | 14,027 | 13,850 | $1.39M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.7% | 6,882 | 6,849 | $694K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.7% | 11,707 | 11,592 | $431K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.6% | 3,934 | 3,924 | $415K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.5% | 9,882 | 9,685 | $381K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 22,874 | 19,861 | $380K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.2% | 3,017 | 3,012 | $317K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.0% | 2,544 | 2,540 | $266K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.0% | 1,785 | 1,773 | $263K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 9,058 | 8,992 | $207K |
114 more codes
| 93882 | <1% | 2,288 | $200K | |
| 93979 | <1% | 2,302 | $186K | |
| 93922 | <1% | 2,553 | $186K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 1,648 | $172K |
| 90461 | <1% | 6,446 | $143K | |
| 92250 | <1% | 2,291 | $139K | |
| 80053 | Comprehensive metabolic panel | <1% | 6,398 | $128K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,257 | $119K |
| 36415 | Collection of venous blood by venipuncture | <1% | 25,376 | $113K |
| 93308 | <1% | 1,696 | $110K | |
| 99441 | <1% | 1,463 | $79K | |
| 99381 | <1% | 459 | $78K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,657 | $60K |
| 83037 | <1% | 6,352 | $59K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 342 | $58K |
| 95117 | <1% | 5,946 | $58K | |
| 76801 | <1% | 364 | $55K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,275 | $54K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 519 | $53K |
| 94010 | <1% | 2,010 | $53K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 8,654 | $49K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 1,728 | $49K |
| 81025 | <1% | 5,669 | $46K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 1,640 | $41K |
| 80061 | Lipid panel | <1% | 3,084 | $41K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,349 | $39K |
| 99442 | <1% | 400 | $39K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,660 | $39K |
| 81003 | <1% | 17,666 | $35K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 119 | $35K |
| 93000 | <1% | 2,421 | $34K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 222 | $34K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 307 | $30K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,585 | $26K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 569 | $23K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 181 | $20K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 572 | $20K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 571 | $19K |
| 99173 | <1% | 529 | $19K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 884 | $19K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 196 | $19K |
| 99384 | <1% | 108 | $18K | |
| 87807 | <1% | 1,279 | $18K | |
| 59426 | <1% | 25 | $17K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 566 | $16K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 501 | $13K |
| 99383 | <1% | 68 | $12K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 82 | $10K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 85 | $9K |
| 99460 | <1% | 95 | $9K | |
| 99382 | <1% | 51 | $9K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,490 | $8K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 57 | $8K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 112 | $8K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,330 | $8K |
| 90670 | <1% | 1,956 | $7K | |
| 72100 | <1% | 223 | $7K | |
| 73562 | <1% | 217 | $6K | |
| 84439 | <1% | 700 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,559 | $5K |
| 95115 | <1% | 662 | $5K | |
| 73630 | <1% | 172 | $4K | |
| 82607 | <1% | 278 | $4K | |
| 76536 | <1% | 50 | $3K | |
| 73610 | <1% | 121 | $3K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 62 | $3K |
| 80050 | General health panel | <1% | 51 | $3K |
| 69210 | <1% | 52 | $2K | |
| 90474 | <1% | 111 | $2K | |
| 90756 | <1% | 121 | $2K | |
| 59025 | Fetal non-stress test | <1% | 53 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 28 | $2K |
| 90863 | <1% | 48 | $2K | |
| 99307 | <1% | 93 | $2K | |
| 99490 | Ccm add 20min | <1% | 254 | $1K |
| 73130 | <1% | 49 | $1K | |
| 82951 | <1% | 101 | $1K | |
| 90674 | <1% | 57 | $1K | |
| 82947 | <1% | 356 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $975.88 |
| 90710 | <1% | 307 | $967.66 | |
| 73110 | <1% | 30 | $857.93 | |
| 90680 | <1% | 384 | $738.37 | |
| 99318 | <1% | 32 | $682.16 | |
| 90734 | <1% | 350 | $662.42 | |
| 99306 | Prolong nursin fac eval 15m | <1% | 16 | $646.29 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 52 | $450.36 |
| 96127 | <1% | 71 | $409.29 | |
| 90647 | <1% | 1,047 | $358.90 | |
| 73030 | <1% | 13 | $326.24 | |
| 73140 | <1% | 13 | $304.21 | |
| 90715 | <1% | 193 | $283.99 | |
| 90686 | <1% | 350 | $267.19 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 457 | $190.67 |
| 90716 | <1% | 388 | $178.85 | |
| 85018 | <1% | 52 | $119.41 | |
| 85014 | <1% | 52 | $119.41 | |
| 90633 | <1% | 1,064 | $72.80 | |
| 90700 | <1% | 264 | $60.18 | |
| 90696 | <1% | 203 | $57.00 | |
| 90707 | <1% | 389 | $52.71 | |
| 90658 | <1% | 28 | $47.76 | |
| 90697 | <1% | 112 | $44.10 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 13 | $32.18 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 13 | $31.38 |
| 90657 | <1% | 19 | $6.02 | |
| 90723 | <1% | 861 | $1.00 | |
| 90698 | 0% | 214 | $0.00 | |
| 90651 | 0% | 77 | $0.00 | |
| 90671 | 0% | 81 | $0.00 | |
| 90649 | 0% | 157 | $0.00 | |
| 90672 | 0% | 39 | $0.00 | |
| 90681 | 0% | 69 | $0.00 | |
| 90713 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHURT, ALLEN (OWNER/ADMINISTRATOR)